Rigel Pharmaceuticals CEO Raul Rodriguez's 2019 pay falls 36% to $2.6M
Rigel Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: April 1, 2020
Rigel Pharmaceuticals reported fiscal year 2019 executive compensation information on April 1, 2020.
In 2019, seven executives at Rigel Pharmaceuticals received on average a compensation package of $1.3M, a 34% decrease compared to previous year.
Average pay of disclosed executives at Rigel Pharmaceuticals
Raul R. Rodriguez, Chief Executive Officer, received $2.6M in total, which decreased by 36% compared to 2018. 61% of Rodriguez's compensation, or $1.6M, was in option awards. Rodriguez also received $351K in non-equity incentive plan, $649K in salary, as well as $9K in other compensation.
Anne-Marie Duliege, Chief Medical Officer, received a compensation package of $1.6M, which decreased by 6% compared to previous year. 54% of the compensation package, or $870K, was in other compensation.
Dolly A. Vance, Executive Vice President, Corporate Affairs, General, earned $1.2M in 2019, a 33% decrease compared to previous year.
Dean L. Schorno, Chief Financial Officer, received $1M in 2019, which decreases by 13% compared to 2018.
Eldon C. Mayer, III, Executive Vice President, Chief Commercial Officer, earned $934K in 2019, a 41% decrease compared to previous year.
Esteban Masuda, Executive Vice President, Research, received $796K in 2019, which decreases by 39% compared to 2018.
Wolfgang Dummer, Chief Medical Officer, earned $779K in 2019.
Related executives
Dolly Vance
Rigel Pharmaceuticals
Executive Vice President, Corporate Affairs, General
Wolfgang Dummer
Rigel Pharmaceuticals
Chief Medical Officer
Esteban Masuda
Rigel Pharmaceuticals
Executive Vice President, Research
Anne-Marie Duliege
Rigel Pharmaceuticals
Chief Medical Officer
Eldon Mayer
Rigel Pharmaceuticals
Executive Vice President, Chief Commercial Officer
Raul Rodriguez
Rigel Pharmaceuticals
Chief Executive Officer
Dean Schorno
Rigel Pharmaceuticals
Chief Financial Officer
You may also like
Source: SEC filing on April 1, 2020.